What are the odds at ASCOT today?

Lancet

Volumn 361, Issue 9364, 2003, Pages 1144-1145

  Lindholm, Lars H ^a   Samuelsson, Ola ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PLACEBO; PRAVASTATIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FOLLOW UP; HEALTH CARE COST; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; TREATMENT OUTCOME;

EID: 0037420503     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12977-7     Document Type: Note

References (9)

1. Moderately elevated blood pressure. A report from SBU, The Swedish Council on Technology Assessment in Health Care. J Intern Med 1995; 238 (suppl 737): S1-S225.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
3. Haffner S.M., Alexander C.M., Cook T.J., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 159:1999;2661-2667.
4. Goldberg R.B., Mellies M.J., Sacks F.M. for the . Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 98:1998;2513-2519.
5. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care; the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 288:2002;2998-3007.
6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2981-2997.
7. Weber M.A. The ALLHAT Report: a case of information and misinformation. J Clin Hypertens. 5:2003;9-13.
8. Ault A. Two ALLHAT investigators say results misinterpreted and misused. Reuters Health, March 19, 2003.
9. Samuelsson O., Wilhelmsen L., Andersson O.K., Pennert K., Berglund G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension: results from the primary prevention trial in Goteborg, Sweden. JAMA. 258:1987;1768-1776.